2023-504063-17-00
Recruiting
Phase 1
A Phase 1 Study of JNJ-87189401 Combined with JNJ-78278343 for Advanced Prostate Cancer
Janssen - Cilag International3 sites in 2 countries48 target enrollmentStarted: February 23, 2024Last updated:
Overview
- Phase
- Phase 1
- Status
- Recruiting
- Enrollment
- 48
- Locations
- 3
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 65+ years (65+ Years, 18-64 Years)
- Sex
- Male
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
CTIS Point of Contact
Scientific
Janssen - Cilag International
Study Sites (3)
Loading locations...
Similar Trials
Recruiting
Phase 1
A Phase 1b Study of JNJ-80948543 in Combination with Other CD3 TCEs for R/R B-cell NHL2024-514176-41-00Janssen Cilag International16
Recruiting
Phase 3
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple MyelomaNCT07258511Janssen Research & Development, LLC400
Recruiting
Phase 2
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple MyelomaNCT07266441Janssen Research & Development, LLC157
Active, not recruiting
Phase 2
An Open Label Study of JNJ-68284528, Directed Against BCMA in Subjects with Multiple Myeloma2023-506587-13-00Janssen - Cilag International56
Recruiting
Phase 1
A First-in-Human Dose Escalation Study of JNJ-79635322, in Participants with Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis2023-503679-12-00Janssen - Cilag International75